• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
74,360.01 13.84
( 0.02%)
Global Indices
Nasdaq
50,746.98 -581.81
(-1.13%)
Dow Jones
7,576.82 -53.96
(-0.71%)
Hang Seng
67,369.16 -1,032.97
(-1.51%)
Nikkei 225
10,347.89 15.59
(0.15%)
Forex
USD-INR
95.24 0.16
(0.17%)
EUR-INR
110.83 0.16
(0.15%)
GBP-INR
128.25 0.32
(0.25%)
JPY-INR
0.60 0.00
(0.02%)

EQUITY - MARKET SCREENER

Fredun Pharmaceuticals Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
539730
INE194R01017
514.6538079
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
38.59
1281.42
EPS(TTM)
Face Value()
Div & Yield %
60.24
10
0
 

Bombay Dyeing slumps on reporting dismal Q3 performance
Feb 12,2026
Revenue from operations declined 21.9% year-on-year to Rs 324.02 crore in the quarter ended 31 December 2025.

The company reported a loss before tax of Rs 12.64 crore in Q3 FY26, as against a profit before tax of Rs 93.91 crore in Q3 FY25.

Total expenses declined 11.17% year-on-year to Rs 362.43 crore during the quarter. The cost of raw materials fell 26.78% to Rs 204.10 crore, while employee benefit expenses surged 451.07% YoY to Rs 48.99 crore.

Meanwhile, the company announced the resignation of Khiroda Jena, chief financial officer & chief risk officer (CFO & CRO) and key managerial personnel of the company, effective from the closure of business hours on 13 February, 2026.

Bombay Dyeing & Manufacturing Company is currently engaged in the business of real estate development, polyester staple fiber, and retail (textiles).